Articles tagged with Cancer Patients
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
The ASCOLT trial found that aspirin does not statistically improve disease-free survival for all patients but demonstrates a consistent trend of improving overall and disease-free survival. Aspirin taken for up to 3 years is efficacious in patients with PIK3CA mutation, reducing recurrence by over 50%.
A combination therapy of FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel is being investigated in a Phase 2 trial for patients with advanced or recurrent endometrial cancer. The trial aims to target the PI3K/AKT/mTOR pathway, which is frequently mutated in cancer.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Recent research suggests that some invasive cancers diagnosed in early-stage breast cancer may not need immediate surgery, highlighting the importance of more precise screening methods for DCIS. The COMET trial found that at least half of invasive breast cancers take years to progress or may never progress at all.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
Researchers are conducting a clinical trial to find the optimal combination of pain management tools for patients undergoing mastectomy procedures. The study will enroll approximately 100 patients and examine various combinations of pectoralis nerve blocks, non-opioid analgesics, and administration methods.
Researchers create microfluidic device to sort tumor cells based on adhesive strength, revealing potential method to predict aggressive cancer behavior. The study's findings offer a promising approach for personalizing treatment plans and identifying high-risk patients.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A new federal mandate aims to improve patient awareness about breast density, which affects cancer detection and risk. Women with dense breasts may need supplemental screening, such as MRI, to detect breast cancer earlier, but this comes with potential downsides.
Researchers have developed a specialized nanoscale material that illuminates cancer cells under freezing conditions, improving surgical precision. This technology enhances surgeons' ability to detect and remove cancer cells during cryosurgery.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Researchers found that training the innate immune system can exacerbate inflammatory bone loss in models of chronic diseases like periodontitis and arthritis. The study suggests that a previously thought beneficial effect of trained immunity may actually contribute to harm in certain contexts.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
A study published in Plastic and Reconstructive Surgery reports that women who undergo breast-conserving therapy (BCT) experience improved sexual well-being compared to those who receive post-mastectomy breast reconstruction (PMBR). Scores on a sexual well-being subscale were consistently higher for BCT patients, with average scores 7....
Increased visceral adipose tissue density and decreased skeletal muscle area are predictors of post-esophagectomy pulmonary complications. Decreased skeletal muscle density is associated with poorer overall survival. Routine morphomic analysis can help identify patients at risk and tailor perioperative care.
A recent study published in CANCER suggests that higher levels of physical activity may lessen and even eliminate survival disparities among colon cancer survivors. Cancer survivors who regularly exercised achieved better subsequent survival rates than those seen in the matched general population, with a 3.1% lower risk at year three.
New research reveals aldosterone-producing adenomas harbor at least four distinct cell types, including cortisol-producing cells that contribute to unexpected health issues. The study also identifies potential role of lipid-associated macrophages in influencing hormone production and tumor growth.
A study of 33,744 Medicare decedents found that 45% received potentially aggressive care in the last days of life, while only 25% received advanced care planning and palliative care. Despite efforts to raise awareness about the harms of aggressive treatment, access to supportive care varies among demographic groups.
A retrospective study found that only one-quarter of patients diagnosed with advanced cancer received palliative care in the last six months of life. The study also showed that 45% of decedents experienced potentially aggressive care, highlighting the need for interventions to improve quality of care.
A recent study has identified that the neuronal subtype responds best to immunotherapy, while other subtypes exhibit lower response rates. The researchers developed a machine-learning algorithm using large public data sets to predict treatment response based on tumor mutational burden and immune cell infiltration.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
A rare case of adenomyosis in an 81-year-old postmenopausal woman closely resembles invasive endometrial cancer, emphasizing the challenges of diagnosing this condition. Further studies are needed to refine diagnostic protocols and determine risk factors for postmenopausal patients.
A pilot study shows that a text messaging system can safely reduce the amount of time some patients spend receiving cancer treatment. The platform, which was tested in a clinical trial, allowed patients to complete symptom checks and receive approval for fast-tracking their treatments, saving them over an hour per visit.
The joint venture aims to build the world's preeminent pediatric cancer center, increasing access to care and clinical trials. Collaborative operations will launch in early 2026, featuring a focus on new facilities with latest medical technology.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
The joint venture will unite the nation's largest comprehensive pediatric system with a top pediatric cancer program and the nation's leading comprehensive cancer center. The collaboration aims to accelerate improved outcomes for patients in Texas and around the world, increasing access to clinical trials and innovative treatments.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
A study found racial and ethnic minorities are less likely to receive standard-of-care diagnostic imaging after abnormal screening mammograms compared to white patients. Minority groups were also less likely to have access to same-day biopsy services, despite similar availability of most diagnostic services.
Researchers at Aston University and the Royal Orthopaedic Hospital are developing an injectable paste using gallium-doped bioglass to treat bone cancer. The substance has anticancer and bone regenerative properties, showing a 99% success rate in eliminating cancerous cells.
Amplified Sciences has received CLIA certification for its PanCystPro test, which helps risk stratify patients with pancreatic cystic lesions. The company plans to commercialize the test through an early access program and a clinical utility trial in 2025.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers found that Black women with triple-negative breast cancer are less likely to receive immunotherapy treatment, even when accounting for socioeconomic factors. The study analyzed data from over 10,000 patients and found a significant disparity in immunotherapy response between racial groups.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
A study found that 77.9% of lung cancer patients had detectable atherosclerosis on CT scans, with smoking being the most prominent cardiac risk factor. The results suggest using concurrent coronary calcium scoring to aid in identification and earlier intervention for these patients.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
A preclinical study reveals that tumors drive clot formation by releasing chemokines, prompting immune cells to release small vesicles that attach to cell fragments, forming life-threatening clots. The findings may lead to diagnostic tests and safer therapies to target the root of blood clotting risk.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
The National Foundation for Cancer Research (NFCR) has launched a new podcast called All Things Cancer. The podcast is hosted by Sujuan Ba, Ph.D., and features conversations with leading scientists, oncologists, doctors, patient advocates, caregivers, biotech innovators, and survivors.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
A multicenter study found that electronic symptom monitoring improved quality of life, clinical outcomes, and well-being in metastatic cancer patients. The PRO-TECT trial showed significant benefits for patients who reported their symptoms via a home-based electronic monitoring system.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A Virginia Tech research team has made significant progress in understanding the role of physical properties in tuning the body's immune responses. By modifying biomaterials' size, shape, and stiffness, they aim to enhance immune cell behavior and stimulate antitumor immune responses.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.